Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
-- ELEVATE-45-201 Cohort 2 (10 mg/kg) enrollment complete with data expected in H1 2027 -- BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc.
